myoscience
REDWOOD CITY, Calif., 2014-05-01 14:00 CEST (GLOBE NEWSWIRE) -- California based myoscience, inc., is pleased to announce the launch of the revolutionary iovera° health treatment, a new option to immediately block pain using the body's natural response to cold without the use of drugs or surgery.
Vinod Dasa, MD, Associate Professor of Orthopaedic Surgery in New Orleans, one of the first to perform the treatment has treated over 50 patients and is excited about the possibilities. "I think this technology has the potential to change the current paradigm of acute and chronic pain management. The patients that I have treated are all grateful to have an option that is very safe and that has allowed them to get back to functionality quickly."
Clint Carnell, CEO of myoscience, has witnessed the powerful patient outcomes "It's rewarding to provide this revolutionary treatment to patients suffering from pain. We have developed a product that delivers a treatment that is safe, effective and most importantly free of the negative systemic side effects often common with today's therapeutic options."
The iovera° health treatment utilizes myoscience's platform technology, the Focused Cold TherapyTM delivery system, to precisely target peripheral nerves, temporarily interrupting pain signaling pathways. This precise cold treatment causes a reversible nerve block based on a process called 2nd degree degeneration that is followed by a predictable restoration of nerve function. The iovera° system offers patients a new treatment option, with no systemic side effects and nothing being injected into the body. Most patients experience instant pain relief after an iovera° treatment, with results that can last up to three months.
For physicians and patients who would like additional information, please visit www.ioverahealth.comor email us directly at contact@myoscience.com.
ABOUT MYOSCIENCE
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system. The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581
© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.
CONTACT: 1600 Seaport Blvd., Ste. 450 / Redwood City, CA
Tel: 650.474.2600 / iovera.com
MEDIA RELATIONS
Jay Patel / myoscience@hypertonic.com
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Sampo plc4.9.2025 07:30:00 CEST | Press release
Sampo plc’s share buybacks 3 September 2025
Wooclap4.9.2025 07:02:26 CEST | Press release
Edtech leader Wooclap raises €25 million from Impact Expansion to accelerate international growth and spearhead innovation in active pedagogy
Verkkokauppa.com Oyj4.9.2025 07:00:37 CEST | Press release
Verkkokauppa.com Oyj has completed the sale of its consumer financing business to Walley
Kuros Biosciences AG4.9.2025 07:00:00 CEST | Press release
Kuros Biosciences announces changes in the Board of Directors
Vivoryon Therapeutics N.V.4.9.2025 07:00:00 CEST | Press release
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum